← All trials
NCT06114628
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 8, 2023
- Primary completion
- Feb 24, 2027
- Completion date
- Aug 11, 2027
- First posted
- Nov 2, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 2500
- Arms / groups
- 12 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- German Center for Infection ResearchCollaborator
- GlaxoSmithKlineCollaborator
- Government of FranceCollaborator
- University of PortoCollaborator
- Janssen Pharmaceutica NVCollaborator
- KNCV Tuberculosis FoundationCollaborator
- University of LondonCollaborator
- OtsukaCollaborator
- Radboud UniversityCollaborator
- TASK Applied ScienceCollaborator
- TB AllianceCollaborator
- Tuberculosis Network European TrialsgroupCollaborator
- University of California, San FranciscoCollaborator
- University of CambridgeCollaborator
- University of HamburgCollaborator
- University of LiverpoolCollaborator
- University of MilanCollaborator
- University of OxfordCollaborator
- Uppsala UniversityCollaborator
- Vita-Salute University of Milano. ItalyCollaborator
- University of St AndrewsCollaborator
- Research Center BorstelCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.